FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	KOVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person [*] Bollard Catherine			2. Issuer Name and Ticker or Trading Symbol Cabaletta Bio, Inc. [CABA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner						
(Last) (First) (Middle) C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600				3. Date of Earliest Transaction (Month/Day/Year) 06/01/2022						Office	(give title below)	Oth	er (specify below))	
(Street) PHILADELPHIA, PA 19104			4. If Amendment, Date Original Filed(Month/Day/Year)					-	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(Cit		(State)	(Zip)	Table I - Non-Derivative Securities Acqu				es Acqui	red, Dispo	sed of, or Ben	eficially Own	ed			
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Dec Executi any (Month	on Date	if Co		(A	4. Securities Acquired (A) or Disposed of (D (Instr. 3, 4 and 5)		Owned Fol Transaction		ed	Ownership o Form: B	7. Nature of Indirect Beneficial Ownership
				(ivionin	, Биу, ТС		Code	· V A	(A) or (D)		or Ind (I)		or Indirect (1	Instr. 4)	
Reminder					119 0 11111	a ance	ily or	i maneetiy.							
Reminder:	Report on a s							in this f displays	orm are not s a currently sed of, or Ben	required valid Ol eficially	d to respo MB contr	on of informa and unless th ol number.		ned SEC 1	474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion	3. Transaction	Table II - 3A. Deemed Execution Date, if	4. Transac Code	tion of Second or of	Number Derivations quired Dispos (D) str. 3, 4	r 6 tive E (A) ed	in this f displays ired, Dispo options, con	orm are not s a currently sed of, or Ben avertible securcisable and Date	required valid Ole eficially rities) 7. Title of Under Securities	d to respondence of the control of t	and unless the ol number.		of 10. Ownership Form of Derivative Security: Direct (D) or Indirec	11. Natur p of Indire Beneficia Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction	Table II - 3A. Deemed Execution Date, if any	4. Transac Code	ts, calls, tion of Second According and	Warra Number Derivate curities quired Dispos (D) str. 3, 4	r 6 tive ((A)) ed 4,	in this f displays ired, Dispo options, con 6. Date Exe Expiration I	orm are not s a currently sed of, or Ben envertible securcisable and Date //Year)	required valid Ole eficially rities) 7. Title of Under Securities	d to responded to responded to responded to and Amore erlying ies	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported	of 10. Ownership Form of Derivative Security: Direct (D) or Indirec	11. Natur p of Indire Beneficie Ownersh (Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Bollard Catherine C/O CABALETTA BIO, INC. 2929 ARCH STREET, SUITE 600 PHILADELPHIA, PA 19104	X					

Signatures

/s/ Michael Gerard, Attorney-in-Fact	06/03/2022
Signature of Reporting Person	Date
·	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This option shall vest in full upon the earlier of (1) June 1, 2023 or (2) the date of the next annual meeting of the Corporation's stockholders.

Remarks:

Exhibit 24: Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Steven Nichtberger, M.D., Anup Marda and Michael Gerard, each acting singly, his true and lawful attorney-in-fact from June 1, 2022 to:

- (1) Execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of Cabaletta Bio, Inc. (the "Company"), forms and authentication documents for EDGAR Filing Access;
- (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete the execution of any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and the timely filing of such form with the United States Securities and Exchange Commission and any other authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary, and proper to be done in the exercise of any of the rights and powers herein granted, as fully for all intents and purposes as the such attorney-in-fact might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

By this Power of Attorney, the undersigned further revokes all previous powers of attorney relating to the undersigned's obligations to file Forms 3, 4 and 5 in respect of the Company's securities under Section 16(a) of the Securities Exchange Act of 1934 and related matters.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date first set forth above.

/s/ Catherine Bollard

Name: Catherine Bollard, MB ChB, M.D.